S K Boyd1, L A Burt, L K Sevick, D A Hanley. 1. McCaig Institute for Bone and Joint Health, University of Calgary, 3280 Hospital Drive, NW, Calgary, Alberta, T2N 4Z6, Canada, skboyd@ucalgary.ca.
Abstract
UNLABELLED: The relation between serum 25-hydroxy vitamin D [25(OH)D] and bone quality is not well understood, particularly for high levels. We measured bone microarchitecture in three groups of people stratified by their serum 25(OH)D. There was a weak association of serum 25(OH)D and microarchitecture for this cross-sectional population, suggesting possible benefits to bone quality. INTRODUCTION: Vitamin D plays an important role in bone and mineral metabolism, but the relation between serum 25(OH)D and bone quality is not well understood. Here, we present a cross-sectional study that investigated a convenience group of participants from an ongoing health initiative in Alberta, Canada, who have been receiving daily vitamin D supplementation. METHODS: A total of 105 participants were organized into three groups based on their serum 25(OH)D levels: low (<75 nmol/L), medium (75-175 nmol/L), and high (>175 nmol/L). They were also assessed with 25(OH)D as a continuous variable. Average daily supplementation was 7670 ± 438 IU, and the change in 25(OH)D ranged from 22 to 33 % during the period of receiving supplements. We used high-resolution peripheral quantitative computed tomography measurements at the radius and tibia to assess bone microarchitecture. RESULTS: Microarchitectural parameters were not strongly associated with serum 25(OH)D. In the tibia, there were fewer trabeculae (TbN; p = 0.015) and a non-significant trend toward thicker trabeculae (p = 0.067) of the high group. Body mass index (BMI) was negatively associated with serum 25(OH)D levels (p < 0.001) and PTH levels (p < 0.001). There was no clinically significant relationship detected between high serum 25(OH)D and high serum calcium. CONCLUSION: These data suggest a weak relationship between serum 25(OH)D and bone microarchitecture in this population of mostly vitamin-D-sufficient participants, and there were no indications of negative effects related to the high supplementation levels. These data provided a basis to design and implement our 3-year dose-dependent randomized controlled trial investigating the effects of vitamin D supplementation on bone health outcomes.
UNLABELLED: The relation between serum 25-hydroxy vitamin D [25(OH)D] and bone quality is not well understood, particularly for high levels. We measured bone microarchitecture in three groups of people stratified by their serum 25(OH)D. There was a weak association of serum 25(OH)D and microarchitecture for this cross-sectional population, suggesting possible benefits to bone quality. INTRODUCTION:Vitamin D plays an important role in bone and mineral metabolism, but the relation between serum 25(OH)D and bone quality is not well understood. Here, we present a cross-sectional study that investigated a convenience group of participants from an ongoing health initiative in Alberta, Canada, who have been receiving daily vitamin D supplementation. METHODS: A total of 105 participants were organized into three groups based on their serum 25(OH)D levels: low (<75 nmol/L), medium (75-175 nmol/L), and high (>175 nmol/L). They were also assessed with 25(OH)D as a continuous variable. Average daily supplementation was 7670 ± 438 IU, and the change in 25(OH)D ranged from 22 to 33 % during the period of receiving supplements. We used high-resolution peripheral quantitative computed tomography measurements at the radius and tibia to assess bone microarchitecture. RESULTS: Microarchitectural parameters were not strongly associated with serum 25(OH)D. In the tibia, there were fewer trabeculae (TbN; p = 0.015) and a non-significant trend toward thicker trabeculae (p = 0.067) of the high group. Body mass index (BMI) was negatively associated with serum 25(OH)D levels (p < 0.001) and PTH levels (p < 0.001). There was no clinically significant relationship detected between high serum 25(OH)D and high serum calcium. CONCLUSION: These data suggest a weak relationship between serum 25(OH)D and bone microarchitecture in this population of mostly vitamin-D-sufficient participants, and there were no indications of negative effects related to the high supplementation levels. These data provided a basis to design and implement our 3-year dose-dependent randomized controlled trial investigating the effects of vitamin D supplementation on bone health outcomes.
Authors: A Catharine Ross; JoAnn E Manson; Steven A Abrams; John F Aloia; Patsy M Brannon; Steven K Clinton; Ramon A Durazo-Arvizu; J Christopher Gallagher; Richard L Gallo; Glenville Jones; Christopher S Kovacs; Susan T Mayne; Clifford J Rosen; Sue A Shapses Journal: J Clin Endocrinol Metab Date: 2010-11-29 Impact factor: 5.958
Authors: M Osima; T T Borgen; M Lukic; G Grimnes; R M Joakimsen; E F Eriksen; Å Bjørnerem Journal: Osteoporos Int Date: 2017-11-14 Impact factor: 4.507
Authors: D E Whittier; S K Boyd; A J Burghardt; J Paccou; A Ghasem-Zadeh; R Chapurlat; K Engelke; M L Bouxsein Journal: Osteoporos Int Date: 2020-05-26 Impact factor: 4.507
Authors: Margaret Garrahan; Sarah Gehman; Sara E Rudolph; Adam S Tenforde; Kathryn E Ackerman; Kristin L Popp; Mary L Bouxsein; Shivani Sahni Journal: J Clin Endocrinol Metab Date: 2022-08-18 Impact factor: 6.134
Authors: Jane A Cauley; Andrew J Burghardt; Stephanie L Harrison; Peggy M Cawthon; Ann V Schwartz; Elizabeth Barrett Connor; Kristine E Ensrud; Lisa Langsetmo; Sharmila Majumdar; Eric Orwoll Journal: J Bone Miner Res Date: 2018-06-12 Impact factor: 6.741
Authors: Marcella D Walker; Kyle K Nishiyama; Bin Zhou; Elaine Cong; Ji Wang; James A Lee; Anna Kepley; Chengchen Zhang; X Edward Guo; Shonni J Silverberg Journal: J Clin Endocrinol Metab Date: 2016-01-08 Impact factor: 5.958